Carterra, Inc.
Surface Plasmon Resonance (SPR) platform for high-throughput vaccine antigen and epitope characterization
- Sector
- Biotech
- Headquarters
- SALT LAKE CITY, UT
- Latest Form D
- $5M, Apr 2024
- Total capital
- $35.6M
- Federal grants
- $3.1M
- 6 awards · 2015–2017
- Rank in peer group#27 of 42
- Private capital raised
- $32.5M
- 7 Form D · last Apr 2024
- 30 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 1
- 10 pending · first 2019
- Rank in peer group#21 of 42
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 7th filing$5M
- Private capital raisedForm D · SEC · 6th filing$6M
- Private capital raisedForm D · SEC · 5th filing$6M
- Private capital raisedForm D · SEC · 4th filing$4.5M
- Federal grantHealth and Human S · Phase II · Improving vaccine development through high-throughput immunogenicity screening.$751K
- Federal grantHealth and Human S · Phase I · High throughput multiplexed characterization and modeling of antibody antigen binding with application to HSV$300K
- Federal grantHealth and Human S · Phase I · High-throughput, multiplexed characterization and modeling of antibody:antigen binding, with application to HSV$300K
- Private capital raisedForm D · SEC · 3rd filing$10.3M
- Private capital raisedForm D · SEC · 2nd filing$483K
- Private capital raisedForm D · SEC · 1st filing$200K
Show 3 earlier federal awards
- Federal grantHealth and Human S · Phase II · Improving vaccine development through high-throughput immunogenicity screening.$752K
- Federal grantHealth and Human S · Phase II · HT Label-Free Screening and Kinetic Analysis of Small Molecules and Biologics$510K
- Federal grantHealth and Human S · Phase II · HT Label-Free Screening and Kinetic Analysis of Small Molecules and Biologics$510K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 42 peers
Line = medianBiotech · Instrument
- Federal grantsBelow median
- Granted patents#21 · top 50%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Alexander HerzickDirectorNamed in SEC Form D filings
- Jack BallDirectorNamed in SEC Form D filings
- Janel FillingerExecutive OfficerNamed in SEC Form D filings
- Joe KeeganDirectorNamed in SEC Form D filings
- John LilligDirectorNamed in SEC Form D filings
- Josh EckmanExecutive Officer, DirectorNamed in SEC Form D filings
What it has protected
USPTO · 1 granted of 11- PendingNon-sequential Scanning Of SubstancesUSPTOApplication 19257586
- PendingFluid Control AdaptersUSPTOApplication 18947269
- PendingMicrofluidic Flow Cell ArraysUSPTOApplication 18410163
Show all 11 patent records
- Non-sequential Scanning Of SubstancesJan 15, 2026 · Application 19257586Pending
- Fluid Control AdaptersMay 15, 2025 · Application 18947269Pending
- Microfluidic Flow Cell ArraysJul 11, 2024 · Application 18410163Pending
- Interstitial Printing Of Microarrays For Biomolecular Interaction AnalysisOct 13, 2022 · Application 17224448Pending
- Tip Overlay For Continuous Flow Spotting ApparatusMay 28, 2019 · US 10,300,479Granted
- Microfluidic Flow Cell ArraysApplication PCTUS2024011205Pending
- Fluid Control AdaptersApplication 63598620Pending
- Microfluidic Flow Cell ArraysApplication 63438329Pending
- Interstitial Printing Of Microarrays For Biomolecular Interaction AnalysisApplication PCTUS2022023887Pending
- Non-sequential Scanning Of SubstancesApplication 63668059Pending
- Non-sequential Scanning Of SubstancesApplication PCTUS2025036208Pending
Related companies, and why
- ARIDIS PHARMACEUTICALS, LLCSimilar federal contract value in Biotech · null in contracts
- FirstString Research, IncSimilar federal contract value in Biotech · null in contracts
- Clover Biopharmaceuticals, Ltd.Similar federal contract value in Biotech · null in contracts
- ACCELERO BIOSTRUCTURES INCSimilar federal contract value in Biotech · null in contracts
- Immunis, Inc.Similar federal contract value in Biotech · null in contracts
- Shift Pharmaceuticals Holdings, Inc.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .